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Introduction: Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described
in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating
polyneuropathy causes paresthesias and weakness, which can make the treatment of lymphoma with chemotherapy
challenging. Given the rarity of this co-presentation it is not known if the effects of Guillain-Barre syndrome should be
considered when selecting a treatment regimen for Hodgkin lymphoma. To the best of our knowledge, the impact of
these treatment modifications has not been previously reported.
Case presentation: We report the case of a 37-year-old Caucasian man with a diagnosis of stage IIB classical Hodgkin
lymphoma with concomitant Guillain-Barre syndrome. Our patient originally presented with an enlarged cervical lymph
node and quickly developed distal paresthesia and progressive weakness of all four extremities. He was diagnosed with
Hodgkin’s lymphoma and initiated on treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine. Doses of
bleomycin and vinblastine were held or dose-reduced throughout his initial treatment course due to underlying
neuropathy and dyspnea. He continued to have persistent disease after five cycles of doxorubicin, bleomycin, vinblastine,
and dacarbazine and went on to receive salvage treatments including more chemotherapy, radiation, autologous stem
cell transplant and is currently preparing for an allogeneic stem cell transplant.
Conclusions: Paraneoplastic syndromes such as Guillain-Barre syndrome/acute inflammatory demyelinating
polyneuropathy can make the treatment of patients with Hodgkin lymphoma more challenging and can interfere
with delivering full-dose chemotherapy. Further case series are needed to evaluate the effect that paraneoplastic
syndromes, or adjustments made in therapy due to these syndromes, negatively affect the prognosis of patients with
Hodgkin lymphoma.
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Paraneoplastic syndromes can develop in patients with
cancer and indicate damage to distant organs or tissues
via mechanisms external to the cancer itself [1,2]. They
are seen in less than 1% of patients with malignancies
and cause a variety of disorders, including hematologic,
dermatologic, renal and neurologic abnormalities [1,2].
Guillain-Barré syndrome (GBS), or acute inflammatory
demyelinating polyneuropathy (AIDP), is characterized
by distal paresthesia and progressive bilateral, symmetric* Correspondence: calhughes@mdanderson.org
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unless otherwise stated.weakness of the extremities [3]. It is often precipitated
by underlying infection, but has also been well described
in the presence of malignancies, particularly lymphomas
[4-10]. Since these associations are rare with only case
reports in the literature, it is not truly known if the presence
of paraneoplastic syndromes, such as GBS, should be
considered when determining treatment intensity, or if
the co-presence of these syndromes affects the prognosis
of patients with underlying lymphoma. We describe the
treatment and course of disease in a young man with
Hodgkin lymphoma (HL) with associated GBS.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,











4/29/11 25 10 None 375
C1D1
5/13/11 25 None None 375
C1D15
5/27/11 25 None 4 375
C2D1
6/16/11 25 10 6 375
C2D15
7/1/11 25 10 6 375
C3D1
7/14/11 25 10 None 375
C3D15
7/29/11 25 10 3 375
C4D1
8/11/11 25 10 3 375
C4D15
8/25/11 25 10 6 375
C5D1
9/08/11 25 None 6 375
C5D15
A, adriamycin; B, bleomycin; C, cycle; D, day; D, dacarbazine; V, vinblastine.
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A 37-year-old Caucasian man with a history of hypertension
presented to his primary care physician with rhinorrhea, a
cough and an enlarged lymph node in the left posterior
neck that had been worsening over the past one to two
months. Our patient was initially treated with a course of
oral antibiotics, but had no improvement in his symptoms.
He then developed intermittent numbness and tingling in
his bilateral feet, which progressed to involve both of his
legs and his fingertips. After a few more days, he developed
weakness in his bilateral lower extremities and his hands. A
computed tomography (CT) scan of his head revealed no
significant abnormalities. A fine-needle aspiration of the
neck lymph node was suggestive of, but not definitive for,
HL. Excisional biopsy of a left supraclavicular lymph node
was consistent with classical HL, nodular sclerosis-type.
Further workup with a positron emission tomography
(PET)/CT scan revealed small volume left cervical,
supraclavicular, axillary and mediastinal lymphadenopathy.
A bone marrow biopsy demonstrated a cellular bone
marrow with a slight increase in eosinophils, but no
evidence of lymphoma, so our patient was given a
diagnosis of stage IIB classical HL. By that time, the
weakness in his arms and legs had become worse and
our patient had experienced at least two episodes of
falling with difficulty getting up without assistance.
Our patient had right facial weakness, three out of
five strength in his bilateral shoulders and hip flexors, four
out of five strength in his knee flexors and decreased
vibratory sensation up to the knees bilaterally. Patellar and
Achilles reflexes were not present.
A magnetic resonance imaging (MRI) scan of his brain
showed no intracranial abnormality. An MRI scan of his
spine showed subtle nerve root enhancement of the
cauda equine, but cerebrospinal fluid was negative for
any evidence of malignant cells with only one white
blood cell present (CSF protein = 205). Findings from an
electromyelogram and nerve conduction study were
consistent with an AIDP or GBS. Our patient received
two days of intravenous immune globulin (IVIG) at a
dose of 1g per kg with complete resolution of his sensory
complaints and improvement in his weakness. Three days
later, his neurologic symptoms had worsened along with
development of some mild shortness of breath.
Plasma exchange was initiated for a course of five days
with resolution of his shortness of breath and mild
improvement of his weakness and sensory deficit.
The following week, chemotherapy with doxorubicin,
bleomycin and dacarbazine was initiated (Table 1).
Vinblastine was originally omitted from the standard doxo-
rubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
regimen to avoid exacerbation of our patient’s neuropathy.
It was added back during cycle 2 and again held after our
patient developed redness and tenderness in his fingertipsfollowing 3a. It was reintroduced at a reduced dose after
cycle 4 and at full dose for cycle 5.
Bleomycin was omitted for cycle 1b and cycle 2a due to
the development of cough and a 20% reduction in diffusion
lung capacity for carbon monoxide (DLCO) on repeat
pulmonary function tests (PFTs), but then reintroduced
once our patient’s cough resolved. It was again omitted
after cycle 5a due to worsening shortness of breath and
further decrease in DLCO on PFTs.
By the start of cycle 2, our patient’s Eastern Cooperative
Oncology Group (ECOG) performance status had
improved from two to one and our patient no longer
needed a cane for ambulation. Our patient was also
treated with another dose of IVIG, which helped further
improve his neurologic symptoms. After cycle 3, a PET/CT
scan showed significant improvement in left neck, left
axillary, left hilar and mediastinal lymph nodes. Since there
was not complete resolution of the lymphadenopathy, our
patient was continued on ABVD. A repeat PET/CT scan
after cycle 5 showed residual disease with an increase in
metabolic activity, so a biopsy was performed of a left neck
lymph node and revealed persistent classical Hodgkin
lymphoma.
Our patient was then treated with ifosfamide, carboplatin,
etoposide (ICE) for two cycles with persistent disease,
gemcitabine and vinorelbine for two cycles with persistent
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with progressive disease. Note that brentuximab can cause
peripheral sensory neuropathy; our patient experienced
numbness and tingling in the lower extremities that
resolved after four days.
Since our patient still only had localized disease at that
point, intensity-modulated radiation therapy (IMRT) was
given to the mediastinum, neck and axilla at a total dose of
30.6Gray (Gy) in 17 fractions with an additional 5.4Gy
boost to the mediastinum and neck. He then underwent
an autologous stem cell transplant with carmustine,
etoposide, cytarabine and melphalan conditioning.
Our patient went into remission for about six months,
but then developed recurrent disease in his right lower
lung. He is currently undergoing chemotherapy with
bendamustine with plans for an allogeneic stem cell
transplant. Interestingly, his neurologic symptoms had
mostly resolved despite the persistence of his HL.
Discussion
This report describes a young man with simultaneous
diagnoses of HL and GBS. Lymphocytes are primary
drivers of the immune process, and dysregulation of the
immune system can be one outcome of lymphocytic
malignancies [11]. In one study of 519 patients with HL,
9% of patients were diagnosed with a lymphoma-associated
autoimmune disease. These autoimmune processes are the
underlying etiology of many of the paraneoplastic disorders
reported for patients with lymphoma [2]. The abnormalities
can be hematologic (autoimmune hemolytic anemias,
immune thrombocytopenic purpura, blood eosinophelia),
dermatologic (Sweet’s syndrome, eosinophilic fasciitis),
renal (glomerulonephritis) or neurologic.
Neurologic effects experienced by a patient with HL can
be the result of the disease itself (infiltration of nerves by
tumor, more likely in non-Hodgkin lymphoma (NHL)
than HL), chemotherapy adverse events (neuropathy from
vinca alkaloids, platinum agents) or paraneoplatic causes
[12]. Neurological paraneoplastic syndromes that have
been reported with HL include limbic encephalitis,
subacute myelopathy, subacute motor neuropathy, GBS,
central pontine myelinolysis, and diffuse cerebritis [13].
GBS is described as an inflammatory immune-regulated
neuropathy [12]. Incidence is rare, occurring in one to two
in 100,000 people worldwide [4] and it is thought to
be related to production of antibodies that can be
triggered by infectious agents such as Campylobacter
jejuni, cytomegalovirus, Epstein-Barr virus, Mycoplasma
pneumonia, Haemophilus influenza, and variacella-zoster.
However, ganglioside and glycolipid targets for the anti-
bodies exist not only in the invading pathogen’s proteins,
but also in the tissues of the nervous system. The resulting
autoimmune response causes demyelination manifesting as
areflexia and ascending motor neuropathy [2]. Similarly,antigens present on the surface of lymphoma cells can also
generate production of antibodies that will attack similar
proteins in the nervous system [1,12].
A standard chemotherapy regimen for first-line
treatment of classical HL is the four-drug combination con-
taining doxorubicin, bleomycin, vinblastine and dacarbazine
(ABVD). Vinblastine can induce numbness and peripheral
neuropathy, and patients with preexisting neurologic disor-
ders may be at higher risk of developing neuropathies from
vinblastine [14]. This presents a difficult challenge in
patients with HL experiencing GBS. In this case, our
patient received full-dose vinblastine for four out of
10 doses, and a reduced dose for three doses.
The neurologic abnormalities of GBS can also manifest
as respiratory symptoms, seen in 25% of cases [15]. This
can complicate decisions to include bleomycin in the
treatment regimen, a drug that has resulted in pulmonary
interstitial infiltrates in 3 to 5% of patients [14]. Our patient
received full doses of bleomycin for seven out of 10 doses,
but it was withheld for three doses due to a decline in re-
spiratory status. Certainly, the mechanism of bleomycin-
induced lung injury differs from that seen in a neurologic
condition such as GBS, but the presence of GBS does make
it more difficult to manage a patient like this in an effort to
maximally treat the patient without causing underlying
damage from chemotherapy agents.
Conclusions
Given the rarity of these syndromes, it is not completely
known what effect, if any, paraneoplastic syndromes have
on the overall prognosis of patients with HL. In this case,
adjustments made to our patient’s initial chemotherapy regi-
men may have decreased the effectiveness of the treatment;
or the use of immunosuppressive agents such as immune
globulin may have potentially stimulated growth of the
lymphoma [1]. Since these treatment effects are unknown,
it would be valuable to complete a comprehensive case
series to estimate the impact of paraneoplastic syndromes
and GBS on outcomes in patients with HL to help guide
future treatment.
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